Brief: Actinium Pharmaceuticals, Inc. And EpicentRx Announce Strategic Research Collaboration To Combine Targeted Radiotherapies With Next Generation Cd47/Sirpα Immunotherapy
05/01/2022 12:51
Jan 5 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS, INC. AND EPICENTRX ANNOUNCE
STRATEGIC
RESEARCH COLLABORATION TO COMBINE TARGETED RADIOTHERAPIES WITH
NEXT GENERATION CD47/SIRPΑ IMMUNOTHERAPY
* ACTINIUM PHARMACEUTICALS INC - COLLABORATION TO EXPLORE
ACTINIUM'S CLINICAL STAGE CD33 TARGETING ARC ACTIMAB-A WITH
EPICENTRX'S CLINICAL STAGE RRX-001
Source text for Eikon: ID:nPn1YF4lYa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities